Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Hinder

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
Clinical Pharmacology and Therapeutics|April 3, 2020
Investigation and Management of Stool Frequency and Consistency Associated With SGLT1 Inhibition by Reducing Dietary Carbohydrate: A Randomized TrialYanLing He, Jül Schofield, Ping Mahling, et al.
Drug Discovery Today|October 9, 2025
The R&D productivity challenge: transforming the pharmaceutical ecosystemAlexander Schuhmacher, Oliver Gassmann, Sebastian Kwisda, et al.
Drug Discovery Today|May 22, 2021
R&D efficiency of leading pharmaceutical companies - A 20-year analysisAlexander Schuhmacher, Lucas Wilisch, Michael Kuss, et al.
Drug Discovery Today|July 28, 2023
Analysis of pharma R&D productivity - a new perspective neededAlexander Schuhmacher, Markus Hinder, Alexander von Stegmann Und Stein, et al.
Journal of Clinical Pharmacology|May 15, 2010
Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxideGezim Lahu, Nassr Nassr, Rolf Herzog, et al.
Thrombosis and Haemostasis|April 21, 2005
Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, with tirofiban in healthy volunteersMarkus Hinder, Anne Paccaly, Annke Frick, et al.
Clinical Pharmacology and Therapeutics|December 21, 2006
Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery diseaseMarkus Hinder, Annke Frick, Pierre Jordaan, et al.
Archives of Disease in Childhood|March 24, 2023
Acceptability of multiple coated mini-tablets in comparison to syrup in infants and toddlers: a randomised controlled studyViviane Klingmann, Markus Hinder, Thomas H Langenickel, et al.
Pharmacology Research & Perspectives|March 18, 2022
Evaluation of cardiac parameters and other safety outcomes of brolucizumab treatment in patients with neovascular age-related macular degenerationNadia Zakaria, Nicolas Guerard, Andres Emanuelli, et al.
Journal of Clinical Pharmacology|January 7, 2006
Pharmacokinetics of otamixaban, a direct factor Xa inhibitor, in healthy male subjects: pharmacokinetic model development for phase 2/3 simulation of exposureAnne Paccaly, Annke Frick, Shashank Rohatagi, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Clinical Pharmacology and Therapeutics|April 3, 2020
Investigation and Management of Stool Frequency and Consistency Associated With SGLT1 Inhibition by Reducing Dietary Carbohydrate: A Randomized TrialYanLing He, Jül Schofield, Ping Mahling, et al.
Drug Discovery Today|October 9, 2025
The R&D productivity challenge: transforming the pharmaceutical ecosystemAlexander Schuhmacher, Oliver Gassmann, Sebastian Kwisda, et al.
Drug Discovery Today|May 22, 2021
R&D efficiency of leading pharmaceutical companies - A 20-year analysisAlexander Schuhmacher, Lucas Wilisch, Michael Kuss, et al.
Drug Discovery Today|July 28, 2023
Analysis of pharma R&D productivity - a new perspective neededAlexander Schuhmacher, Markus Hinder, Alexander von Stegmann Und Stein, et al.
Journal of Clinical Pharmacology|May 15, 2010
Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxideGezim Lahu, Nassr Nassr, Rolf Herzog, et al.
Thrombosis and Haemostasis|April 21, 2005
Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, with tirofiban in healthy volunteersMarkus Hinder, Anne Paccaly, Annke Frick, et al.
Clinical Pharmacology and Therapeutics|December 21, 2006
Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery diseaseMarkus Hinder, Annke Frick, Pierre Jordaan, et al.
Archives of Disease in Childhood|March 24, 2023
Acceptability of multiple coated mini-tablets in comparison to syrup in infants and toddlers: a randomised controlled studyViviane Klingmann, Markus Hinder, Thomas H Langenickel, et al.
Pharmacology Research & Perspectives|March 18, 2022
Evaluation of cardiac parameters and other safety outcomes of brolucizumab treatment in patients with neovascular age-related macular degenerationNadia Zakaria, Nicolas Guerard, Andres Emanuelli, et al.
Journal of Clinical Pharmacology|January 7, 2006
Pharmacokinetics of otamixaban, a direct factor Xa inhibitor, in healthy male subjects: pharmacokinetic model development for phase 2/3 simulation of exposureAnne Paccaly, Annke Frick, Shashank Rohatagi, et al.
Pageof 5